Daniel Alain, an industry leader in solutions for hair loss and regrowth, has appointed Professor Andy Goren chief medical officer. 

 

Professor Goren will serve as head clinical advisor and will continue to grow his existing relationship with Daniel Alain as the brand’s key researcher and developer of its hair regrowth technology.

 

“I am honored to join Daniel Alain as its first-ever chief medical officer and look forward to sharing my experience to further the mission of Daniel Alain – to bring more hair-loss solutions to a wider audience of patients and consumers,” said Goren. “We have already begun to establish an even broader vision for the company’s direction and growth, as well as more innovation within their product offerings. Along with Daniel himself, we are optimistic this will provide positive evolution within the hair loss community.”

 

The news of the appointment elevates Professor Goren’s partnership with Daniel Alain; the two collaborated previously to develop a first-of-its kind, at-home test for predicting minoxidil response in androgenetic alopecia (Minoxidil Response Test), which was then commercialized by the company. With this new role, Professor Goren will increase the company’s research, development and commercialization of hair-loss focused solutions, and will also preside over the company’s new advisory board, to be announced later this spring.

 

“To say we are honored to work with Professor Goren is an understatement,” said Daniel Hafid, president and CEO of the company. “His well-regarded experience will be an immeasurable asset to Daniel Alain and our growing scientific breakthroughs for hair loss. Goren’s appointment to this newly created position will help guide the brand to new heights.” 

 

Based in Rome, Italy and Prague, Czech Republic, Professor Goren is one of the best-known and most respected in the field of clinical dermatology and trichology, having published dozens of peer-reviewed original medical research papers. He is also an honorary member of several dermatology societies globally, as well as a regular lecturer at dermatology congresses around the world. Most notably, he has been actively involved in the development, commercialization and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy induced alopecia, excessive hair shedding, female sexual dysfunction and covid-19.